Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Lemtrada
(United States) [Available]Synonyms :
Alemtuzumab
Class :
Antineoplastics and Monoclonal Antibody
Brand Name :
Lemtrada
(United States) [Available]Synonyms :
Alemtuzumab
Class :
Antineoplastics and Monoclonal Antibody
Dosage Forms & Strengths  Â
Solution  Â
10mg/ml  Â
30mg/ml   Â
As first course treatment:
Administer a dose of 12 mg as intravenous route every 4 hours daily for 5 days
As second course treatment:
Administer a dose of 12 mg as intravenous route every 4 hours daily for 3 consecutive days given for one year after completion of first course treatment
As maintenance dose:
Administer a dose of 12 mg as intravenous route every 4 hours daily for 3 consecutive days
 Dosage Forms & Strengths  Â
Injectable solution  Â
10mg/ml  Â
30mg/ml  Â
For >17 years old:
As first course treatment:
Administer a dose of 12 mg as intravenous route every 4 hours daily for 5 days
As second course treatment:
Administer a dose of 12 mg as intravenous route every 4 hours daily for 3 consecutive days given for one year after completion of first course treatment
As maintenance dose:
Administer a dose of 12 mg as intravenous route every 4 hours daily for 3 consecutive days
may increase the risk or severity of adverse effects when combined
myelosuppressive activities of lipegfilgrastim can increase if alemtuzumab is used in combination
when both drugs are combined, the risk or severity of infection increases  
when both drugs are combined, the risk or severity of adverse effects increases  
when both drugs are combined, the risk or severity of neutropenia increases  
when both drugs are combined, there may be an increased effect of immunosuppressive activities of fingolimod  
influenza virus vaccine h n live
when both drugs are combined, there may be a reduced effect on the therapeutic activity of the vaccine  
influenza virus vaccine live trivalent
when both drugs are combined, there may be a reduced effect on the therapeutic activity of the vaccine  
when both drugs are combined, the risk or severity of adverse effects increases  
when both drugs are combined, there may be a reduced effect on the therapeutic activity of the vaccine  
when both drugs are combined, there may be a reduced effect on the therapeutic activity of the vaccine  
when both drugs are combined, the risk or severity of adverse effects increases  
when both drugs are combined, the risk or severity of adverse effects increases  
when both drugs are combined, there may be a reduced effect on the therapeutic activity of the vaccine  
when both drugs are combined, the risk or severity of adverse effects increases  
in combination with ofatumumab, alemtuzumab increases the risk of adverse events.
when both drugs are combined, the risk or severity of adverse effects increases  
when both drugs are combined, the risk or severity of bleeding increases  
when both drugs are combined, the risk or severity of adverse effects increases  
when both drugs are combined, the risk or severity of adverse effects increases  
when both drugs are combined, the risk or severity of adverse effects increases  
when both drugs are combined, the risk or severity of adverse effects increases  
when both drugs are combined, the risk or severity of adverse effects increases  
when both drugs are combined, the risk or severity of adverse effects increases  
when both drugs are combined, the risk or severity of adverse effects increases  
when both drugs are combined, the risk or severity of bleeding increases  
when both drugs are combined, the risk or severity of adverse effects increases  
when both drugs are combined, the risk or severity of adverse effects increases  
when both drugs are combined, the risk or severity of adverse effects increases  
when both drugs are combined, the risk or severity of adverse effects increases  
when both drugs are combined, the risk or severity of adverse effects increases 
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
it may enhance the adverse effects when combined with aducanumab
It may diminish the effects when combined with rozanolixizumab by receptor binding competition
The potential for bleeding risk or its seriousness may elevate when alemtuzumab is used together with troxerutin
When mometasone furoate is used together with alemtuzumab, this leads to enhanced risk or seriousness of adverse outcomes
When alemtuzumab is used together with capsaicin, this leads to enhanced risk or seriousness of methemoglobinemia
When andrographolide is used together with alemtuzumab, this leads to enhanced risk or seriousness of bleeding
the chances of adverse effects can be raised when alemtuzumab is combined with volociximab
technetium Tc-99m arcitumomabÂ
the extent of adverse effects can be raised when alemtuzumab is combination
dengue vaccine efficacy will be reduced by alemtuzumab by immunosuppression
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both the drugs are combined, the risk or severity of adverse effects increases    
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk of serious infections   
when both drugs are combined, there may be an increased risk of serious infections  
when both drugs are combined, there may be an increased risk of serious infections  
when both drugs are combined, there may be an increased risk or severity of adverse effects  
When both drugs are combined, there may be an increased risk of severe and possibly life-threatening infections  
the risk of adverse effects may be increased
Actions and spectrum:Â Â Â
Alemtuzumab is a human IgG-derived monoclonal antibody which binds to the CD52 antigen on T and B lymphocytes, NK cells, and monocytes. Â
Frequency defined  Â
>10%  Â
Anemia  Â
Nausea  Â
Diarrhea  Â
Oropharyngeal pain  Â
Immunogenicity  Â
Herpes viral infection  Â
Fungal infection Â
Cytomegalovirus  Â
Nasopharyngitis Â
Abdominal pain  Â
Vomiting    Â
<10%  Â
Decrease in T-lymphocyte count  Â
Purpura  Â
Influenza  Â
Neutropenic fever    Â
Bronchitis  Â
Febrile neutropenia  Â
Leukopenia  Â
Hiccup Â
Flatulence  Â
Oral candidiasis  Â
Frequency not defined  Â
Duodenal ulcer  Â
Melena  Â
Peptic ulcer  Â
Pseudomembranous colitis  Â
Colitis Â
Black Box Warning:Â Â
None Â
Contraindication/Caution:Â Â
Contraindications:Â
Hypersensitivity Â
HIVÂ Â
Active infection Â
Pregnancy Warnings:Â
Pregnancy category: N/AÂ
Lactation: Excretion of the drug into the human breast milk is unknownÂ
Pregnancy categories:Â
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.Â
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.Â
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.Â
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.Â
Category N: There is no data available for the drug under this categoryÂ
Pharmacology Â
It involves lysis of CD52-positive cells through antibody-dependent cytotoxicity, complement activation, and apoptosis. Â
This action targets to modulate and decrease specific immune cell populations which contributes to therapeutic effects.Â
Pharmacodynamics:Â Â Â
The presence of CD52 on normal lymphocytes and monocytes predicts increased neutropenia, lymphopenia, and infectious complications.Â
Administration:Â Â
It is administered by intravenous infusion.Â
Patient information leafletÂ
Generic Name: alemtuzumabÂ
Pronounced: a-LEM-too-zoo-mabÂ
Why do we use alemtuzumab?Â
Alemtuzumab is used to treat chronic lymphocytic leukemia (CLL), a type of blood cancer, and multiple sclerosis (MS). It works by targeting and marking abnormal cells for destruction by the immune system and helps regulate immune activity to reduce attacks on the nervous system.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
